Research Analysts Set Expectations for TSE:MDP Q3 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Analysts at Bloom Burton reduced their Q3 2025 EPS estimates for shares of Medexus Pharmaceuticals in a research note issued to investors on Monday, November 11th. Bloom Burton analyst D. Martin now expects that the company will earn $0.04 per share for the quarter, down from their previous forecast of $0.07. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Bloom Burton also issued estimates for Medexus Pharmaceuticals’ Q4 2025 earnings at $0.01 EPS, FY2025 earnings at $0.19 EPS, FY2026 earnings at $0.18 EPS and FY2027 earnings at $0.13 EPS.

Several other research firms also recently issued reports on MDP. Leede Financial set a C$8.25 price target on shares of Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research note on Monday, September 30th. Stifel Canada raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Monday, August 12th. Finally, Stifel Nicolaus raised their price target on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the company a “buy” rating in a research note on Thursday, August 22nd.

Medexus Pharmaceuticals Stock Performance

MDP stock opened at C$2.04 on Wednesday. The company has a fifty day moving average price of C$2.52 and a 200-day moving average price of C$2.18. The company has a market capitalization of C$50.04 million, a P/E ratio of 40.80 and a beta of 1.96. Medexus Pharmaceuticals has a 52-week low of C$1.44 and a 52-week high of C$3.16.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.